Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain

Álvaro Hidalgo-Vega (), Juan Ramos-Goñi () and Renata Villoro ()

The European Journal of Health Economics, 2014, vol. 15, issue 9, 917-925

Abstract: Ranolazine is a highly efficient add-on therapy for the symptomatic treatment of chronic angina pectoris in patients who are inadequately controlled by, or intolerant to, first-line antianginal therapies in Spain. Copyright Springer-Verlag Berlin Heidelberg 2014

Keywords: Ranolazine, Costs, Utility, Angina, Pectoris, Placebo, I12 - Health Production, H51 - Government Expenditures and Health, D61 - Allocative Efficiency; Cost–Benefit Analysis, (search for similar items in EconPapers)
Date: 2014
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.1007/s10198-013-0534-8 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:15:y:2014:i:9:p:917-925

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-013-0534-8

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().